Company: SMNR
Filing Date: 2025-06-11
Form Type: CORRESP
Source: 0001193125-25-139135
Chunk: 4

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: CORRESP
Chunk 4
---
, 2025 Proposal 3 – The Charter Approval Proposal Reasons for the Approval of the Charter Approval Proposal, page 231

| 10. | We note your response to prior comment 28. Please revise your disclosure in this section to disclose the                                                        
 number of additional authorized shares (i.e., what portion of the proposed increase in authorized shares), if any, needed to complete the Business Combination. |

Response: The Company respectfully advises the Staff that it has revised the disclosure on pages 234-235 of Amendment No. 2 in response to the Staff’s comment. Proposal 7 – The Nasdaq Proposal, page 245

| 11. | We note your statement that you are required to obtain stockholder approval of the Nasdaq Proposal pursuant                                                                                                                                               
 to Nasdaq Listing Rules 5635(a) and (b). Please revise your disclosure in this section to state that your securities have been delisted from Nasdaq and to clarify whether, given such delisting, approval of the Nasdaq Proposal is required to complete 
 the Business Combination and whether the Nasdaq Proposal is still a Condition Precedent Proposal.                                                                                                                                                         |

Response: The Company respectfully advises the Staff that it has revised the disclosure on page 249 of Amendment No. 2 in response to the Staff’s comment. Our Company, page 287

| 12. | We refer to prior comment 29 and note your disclosures on page 288 and elsewhere concerning the Type C                                                                                                                                             
 meeting that Scilex/Semnur had with FDA in November 2023. Please revise to explain in greater detail the specific disagreement between the parties and the guidance regarding expectations for the additional confirmatory trial needed prior to a 
 505(b)(2) NDA filing. In this regard, it is unclear whether FDA was concerned about the size of the completed CLEAR-1 trial, the endpoints assessed or not assessed in the trial, the results reported, or                                         
 something else.                                                                                                                                                                                                                                    |

Response: The Company acknowledges the Staff’s comment and respectfully advises the Staff that the FDA did not express disagreement with, or concerns about, the size, the endpoints, or results of the completed CLEAR-1trial. In fact, the FDA had not yet been provided with full access to the clinical data of the CLEAR-1trial prior to the Type C meeting. As a precautionary measure, the FDA requested a confirmatory CLEAR-2trial, which request was due to the fact that there are currently no FDA-approvedepidural steroid products for